文献速递临床试验与 GCP

锌预防糖尿病前期进展(ZIPPeD研究)——澳大利亚随机安慰剂对照试验的研究方案

Zinc in Preventing the Progression of pre-Diabetes (ZIPPeD Study) - study protocol for a randomised placebo-controlled trial in Australia.
PubMed 文献 · Trials · 2019-04-15

ZIPPeD研究是一项在澳大利亚新南威尔士州开展的随机、安慰剂对照、双盲临床试验,计划招募410名40-70岁、HbA1c 5.7-6.4的糖尿病前期患者。所有参与者接受常规电话健康指导,随后随机接受葡萄糖酸锌(相当于30 mg元素锌)或安慰剂治疗12个月,主要结局为HbA1c和胰岛素敏感性,主要疗效终点在6个月时判定。

要点

  • 锌可能改善血糖控制,但在糖尿病前期人群中的效果尚不确定。
  • 研究纳入HbA1c 5.7-6.4的40-70岁糖尿病前期患者410名。
  • 所有参与者接受电话健康指导,随机加用葡萄糖酸锌(元素锌30 mg)或安慰剂12个月。

核心结论

  • 该研究将生成关于健康指导联合或不联合锌补充改善血糖处理并最终减少糖尿病前期向糖尿病进展的新证据。

研究设计与样本

  • 随机、安慰剂对照、双盲临床试验,在澳大利亚新南威尔士州Hunter New England地方卫生区开展。
  • 计划招募410名40-70岁、HbA1c 5.7-6.4的男性和女性糖尿病前期参与者,通过Diabetes Alliance Network招募。
  • 所有参与者接受常规护理,通过电话指导服务(Get Healthy Information and Coaching Service, NSW Health)鼓励健康生活方式改变。
  • 参与者随机接受葡萄糖酸锌(相当于30 mg元素锌)或外观相同的安慰剂,为期12个月,研究者和参与者均设盲。
  • 参与者在全科医生诊所完成医学、生活方式和饮食调查,并在基线和最终访视时采集数据。

主要发现

  • 主要结局为基线和1、6、12个月时的HbA1c和胰岛素敏感性。
  • 次要结局包括空腹血糖、空腹胆固醇、血压和体重指数。
  • 主要疗效终点在6个月时判定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes is increasing in incidence, morbidity and treatment costs globally, hence prevention strategies need to be explored. Animal studies and some human data have shown that zinc can improve glycaemic control, but the impact of this effect in a pre-diabetic population remains uncertain. This study is designed to investigate whether zinc gluconate and lifestyle coaching can improve glucose handling and ultimately reduce diabetes incidence in an at-risk pre-diabetic population in Australia. METHODS/DESIGN: The study will be a randomised, placebo-controlled, double-blind clinical trial. The study will be conducted at the Hunter New England Local Health District New South Wales (NSW), Australia. Pre-diabetic (haemoglobin A1c [HbA1c] 5.7-6.4) male and female participants (n = 410) aged 40-70 years will be recruited through the Diabetes Alliance Network, a collaboration of diabetes specialists and general practitioner practices. All participants will be given routine care to encourage healthy lifestyle changes using a telephone coaching service (Get Healthy Information and Coaching Service, NSW Health) and then randomised to receive a supplement, either zinc gluconate (equivalent to 30 mg of elemental zinc) or placebo of identical appearance for 12 months. The identity of the supplements will be blinded to both research personnel and the participants. Participants will be asked to complete medical, lifestyle and dietary surveys and will have baseline and final visits at their general practitioner practice. Primary outcomes will be HbA1c and insulin sensitivity collected at baseline and at 1, 6 and 12 months; secondary outcomes will include fasting blood glucose, fasting cholesterol, blood pressure and body mass index. The primary efficacy endpoint will be judged at 6 months. DISCUSSION: This study will generate new evidence about the potential for health coaching, with or without zinc supplementation, to improve glucose handling and ultimately to reduce progression from pre-diabetes to diabetes. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry, ACTRN12618001120268 . Registered on 6 July 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Peel R, Hure A, Wiggers J, et al. Zinc in Preventing the Progression of pre-Diabetes (ZIPPeD Study) - study protocol for a randomised placebo-controlled trial in Australia. Trials. 2019. PMID: 30992081. doi:10.1186/s13063-019-3317-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。